Scholars Central

Review articlePublished 8 Apr 2022

The Application and Progress of Immune Checkpoint Inhibitors in the Immunotherapy of Non-Small Cell Lung Cancer

Authors: Dou Peng Hui, Hounsinou Giscard Kevin Joanes, Zun Xian Wang, Linrui Li, Meiqi Lu

Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Jiamusi University, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

For several years now, the therapeutic situation in the management of non-small cell lung cancer using the immunotherapy protocol has allowed the approval of several drugs. These different drugs have shown fantastic results but with the downside of some side effects whether in monotherapy or in dual therapy with chemotherapy or radiotherapy. The aim of our work was to review the different drugs administered in first- or second-line therapy for non-smallcell lung cancer and other drugs that are still in clinical research or have been dropped. In view of all this, the vaccine is being considered, but its application is still very much in doubt in the scientific community.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Inflammation, Cancer and Integrative Therapy
  • SubjectImmunology & Microbiology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Dou Peng Hui”
  • BylineArticles whose byline prints “Hounsinou Giscard Kevin Joanes”
  • BylineArticles whose byline prints “Zun Xian Wang”
  • BylineArticles whose byline prints “Linrui Li”
  • BylineArticles whose byline prints “Meiqi Lu”